BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38164857)

  • 1. Investigating the prognostic value of m6A methylation-related genes in renal cell carcinoma patients.
    Ge GC; Wang CH
    Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):11932-11946. PubMed ID: 38164857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.
    Jiang T; Xing L; Zhao L; Ye Z; Yu D; Lin S
    BMC Med Genomics; 2023 May; 16(1):105. PubMed ID: 37194014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.
    Zou Y; Jiang G; Xie Y; Li H
    Comput Math Methods Med; 2022; 2022():2427987. PubMed ID: 36339682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. m
    Hou J; Shan H; Zhang Y; Fan Y; Wu B
    Am J Otolaryngol; 2020; 41(4):102547. PubMed ID: 32474328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-methyladenosine methylation-related genes
    Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
    Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential role of RNA N6-methyladenosine in primary Sjögren's syndrome.
    Xiao Q; Wu X; Deng C; Zhao L; Peng L; Zhou J; Zhang W; Zhao Y; Fei Y
    Front Med (Lausanne); 2022; 9():959388. PubMed ID: 36465909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
    Zhao Z; Cai Q; Zhang P; He B; Peng X; Tu G; Peng W; Wang L; Yu F; Wang X
    Front Mol Biosci; 2021; 8():657087. PubMed ID: 34179079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 9. The Cancer Genome Atlas (TCGA) based m
    Liu J; Sun G; Pan S; Qin M; Ouyang R; Li Z; Huang J
    Bioengineered; 2020 Dec; 11(1):759-768. PubMed ID: 32631107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival.
    Zhao J; Lu L
    Recent Pat Anticancer Drug Discov; 2021; 16(3):363-376. PubMed ID: 33563180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma.
    Zhang Y; Li L; Ye Z; Zhang L; Yao N; Gai L
    Ann Transl Med; 2021 Oct; 9(20):1554. PubMed ID: 34790760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma.
    Zhang D; Zhang D; Wang C; Yang X; Zhang R; Li Q; Xiong Y
    Eur J Cancer Prev; 2022 Jul; 31(4):354-362. PubMed ID: 34519693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a m
    Chen J; Yu K; Zhong G; Shen W
    Cancer Cell Int; 2020; 20():157. PubMed ID: 32419773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder.
    Zheng B; Wang J; Zhao G; Chen X; Yao Z; Niu Z; He W
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33779704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
    Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
    Front Immunol; 2022; 13():976107. PubMed ID: 36091006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma.
    Wei J; Qian Y; Tang Y; Ge X; Jiang K; Fang Y; Fu D; Kong X; Xiao Q; Ding K
    Onco Targets Ther; 2021; 14():413-426. PubMed ID: 33488096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer.
    Zhao H; Xu Y; Xie Y; Zhang L; Gao M; Li S; Wang F
    Front Cell Dev Biol; 2021; 9():650023. PubMed ID: 33748145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic risk signature based on the expression of three m6A RNA methylation regulatory genes in kidney renal papillary cell carcinoma.
    Sun Z; Jing C; Xiao C; Li T; Wang Y
    Aging (Albany NY); 2020 Nov; 12(21):22078-22094. PubMed ID: 33177247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.
    Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y
    FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer.
    Xu LC; Pan JX; Pan HD
    Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.